IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer

American Journal of Surgical Pathology

Volumn 35, Issue 11, 2011, Pages 1638-1645

  Lu, Di ^a   Yang, Xiaofang ^a   Jiang, Naomi Y ^b   Woda, Bruce A ^a   Liu, Qin ^c   Dresser, Karen ^a   Mercurio, Arthur M ^a   Rock, Kenneth L ^a   Jiang, Zhong ^a  

^a Three Biotech ^*  (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

cervical dysplasia; cervical invasive squamous cell carcinoma; IMP3; prognostic biomarker; squamous intraepithelial neoplasia

Indexed keywords

IMP3 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HELA CELL; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; TIME; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

ADULT; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HELA CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MASSACHUSETTS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RNA INTERFERENCE; RNA-BINDING PROTEINS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 80054985905     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31823272d4     Document Type: Article

References (35)

1. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA. 1989;262: 931-934.
2. Branca M, Giorgi C, Santini D, et al. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol. 2005;124:113-121. (Pubitemid 40944383)
3. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22: 91-113. (Pubitemid 32452500)
4. Davey DD, Neal MH, Wilbur DC, et al. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004;128:1224-1229. (Pubitemid 39441643)
5. Gad C. The management and natural history of severe dysplasia and carcinoma in situ of the uterine cervix. Br J Obstet Gynaecol. 1976;83:554-559.
6. Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008;112:1471-1479. (Pubitemid 351441159)
7. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252-258. (Pubitemid 29090994)
8. Howley P. Papillomavirinae and Their Replication. New York: Raven Press; 1991.
9. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564. (Pubitemid 43923666)
10. Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 2008;14:5579-5584.
11. Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 2008;112:2676-2682. (Pubitemid 351969211)
12. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489-498. (Pubitemid 43208905)
13. Kyrgiou M, Tsoumpou I, Vrekoussis T, et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev. 2006;32:516-523. (Pubitemid 44464136)
14. Li C, Rock KL, Woda BA, et al. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 2007;20:242-247. (Pubitemid 46422179)
15. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517-18524. (Pubitemid 41389102)
16. Lu D, Vohra P, Chu PG, et al. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 2009;33:521-525.
17. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425-434.
18. Merdek KD, Yang X, Taglienti CA, et al. Intrinsic signaling functions of the beta4 integrin intracellular domain. J Biol Chem. 2007;282:30322-30330. (Pubitemid 350035301)
19. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733. (Pubitemid 27283112)
20. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95-99. (Pubitemid 29467415)
21. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001;234:93-99. (Pubitemid 33043632)
22. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19: 1262-1270. (Pubitemid 29046868)
23. Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004;291:2100-2106. (Pubitemid 38580153)
24. Sankaranarayanan R. Overview of cervical cancer in the developing world. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1): S205-S210.
25. Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008;14:1701-1706. (Pubitemid 351469454)
26. Sjoborg KD, Vistad I, Myhr SS, et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand. 2007;86:423-428. (Pubitemid 46747718)
27. Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J. 2006;25:1456-1468.
28. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002;38:2229-2242. (Pubitemid 35346464)
29. Wang SS, Trunk M, Schiffman M, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13:1355-1360. (Pubitemid 39071561)
30. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer. 2003;88:887-894. (Pubitemid 36520876)
31. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers. 2007;23:315-330. (Pubitemid 47015791)
32. Wright TC Jr. Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340-345.
33. Yaniv K, Fainsod A, Kalcheim C, et al. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development. 2003;130:5649-5661. (Pubitemid 37540841)
34. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195. (Pubitemid 40170636)
35. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304-315. (Pubitemid 351172146)